Jean-Paul Clozel, Idorsia CEO (Patrick Straub/Keystone via AP Images)
February 6, 2023 07:35 AM ESTUpdated 08:16 AM
R&D

Idor­si­a's brain bleed drug flunks PhI­II tri­al, a decade af­ter pre­vi­ous flop

Kyle LaHucik

Senior Reporter

Idor­sia’s long jour­ney with cla­zosen­tan came to an abrupt “un­ex­pect­ed re­sult” Mon­day morn­ing with a Phase III flop.

The Swiss bio­phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

The drug lob­by's law­suit against the IRA finds a sign of life af­ter ap­peals court rul­ing

Biotech VC firm out­lines plans for $100M fund

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times